These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37265786)

  • 1. Transcriptomic signature defines two subtypes of locally advanced PCa with distinct neoadjuvant therapy benefits.
    Zhu Y; Fan L; Zhu H; Gong Y; Chi C; Wang Y; Pan J; Dong B; Xue W
    Front Oncol; 2023; 13():963411. PubMed ID: 37265786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
    Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
    Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy.
    Wang Y; Wu G; Fan L; Pan J; Gong Y; Fei X; Du X; Zhu Y; Xue W
    Prostate; 2021 Jun; 81(8):463-468. PubMed ID: 33822399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant hormonal therapy in carcinoma of the prostate.
    Lee HH; Warde P; Jewett MA
    BJU Int; 1999 Mar; 83(4):438-48. PubMed ID: 10210568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential response to neoadjuvant hormonal therapy in prostate cancer: Predictive morphological parameters and molecular markers.
    Wang X; Qi M; Zhang J; Sun X; Guo H; Pang Y; Zhang Q; Chen X; Zhang R; Liu Z; Liu L; Hao X; Han B
    Prostate; 2019 May; 79(7):709-719. PubMed ID: 30825345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Head-to-head comparisons of [
    Ke ZB; Chen SM; Chen JY; Chen SH; You Q; Sun JB; Xue YT; Sun XL; Wu XH; Zheng QS; Wei Y; Xue XY; Xu N
    Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1240-1251. PubMed ID: 36416906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Neoadjuvant Chemohormonal Therapy in Oligometastatic Hormone-Sensitive Prostate Cancer: A Prospective, Three-Arm, Comparative Propensity Score Match Analysis.
    Chi C; Fan L; Dong B; Zhu Y; Xin Z; Pan J; Xue W
    Clin Genitourin Cancer; 2021 Aug; 19(4):e223-e234. PubMed ID: 33824096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis.
    Narita S; Nara T; Kanda S; Numakura K; Saito M; Inoue T; Satoh S; Nanjo H; Tsuchiya N; Mitsuzuka K; Koie T; Kawamura S; Ohyama C; Tochigi T; Arai Y; Habuchi T
    Clin Genitourin Cancer; 2019 Feb; 17(1):e113-e122. PubMed ID: 30391137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations.
    Chi C; Liu J; Fan L; Zhu Y; Wang Y; Sha J; Huang Y; Dong B; Pan J; Xue W
    Ther Adv Med Oncol; 2022; 14():17588359221128356. PubMed ID: 36199621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.
    Roach M; DeSilvio M; Lawton C; Uhl V; Machtay M; Seider MJ; Rotman M; Jones C; Asbell SO; Valicenti RK; Han S; Thomas CR; Shipley WS;
    J Clin Oncol; 2003 May; 21(10):1904-11. PubMed ID: 12743142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.
    Miyata Y; Nakamura Y; Yasuda T; Matsuo T; Ohba K; Furusato B; Fukuoka J; Sakai H
    Prostate; 2017 Oct; 77(14):1408-1415. PubMed ID: 28845514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
    Thalgott M; Horn T; Heck MM; Maurer T; Eiber M; Retz M; Autenrieth M; Herkommer K; Krause BJ; Gschwend JE; Treiber U; Kübler HR
    J Hematol Oncol; 2014 Mar; 7():20. PubMed ID: 24598155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Hormonal Therapy for Prostate Cancer: Morphologic Features and Predictive Parameters of Therapy Response.
    Wang X; Zhang J; Han B
    Adv Anat Pathol; 2022 Jul; 29(4):252-258. PubMed ID: 35670702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy.
    Stewart SB; Cheville JC; Sebo TJ; Frank I; Boorjian SA; Thompson RH; Gettman MT; Tollefson MK; Umbriet EC; Psutka SP; Bergstralh EJ; Rangel L; Karnes RJ
    Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):332-7. PubMed ID: 25156060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.
    Tosco L; Laenen A; Briganti A; Gontero P; Karnes RJ; Albersen M; Bastian PJ; Chlosta P; Claessens F; Chun FK; Everaerts W; Gratzke C; Graefen M; Kneitz B; Marchioro G; Salas RS; Tombal B; Van den Broeck T; Moris L; Battaglia A; van der Poel H; Walz J; Bossi A; De Meerleer G; Haustermans K; Van Poppel H; Spahn M; Joniau S
    Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):407-412. PubMed ID: 28485390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer.
    Sasaki T; Nishikawa K; Kato M; Masui S; Yoshio Y; Sugimura Y; Inoue T
    Med Sci (Basel); 2021 Apr; 9(2):. PubMed ID: 33918590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
    Roach M; Moughan J; Lawton CAF; Dicker AP; Zeitzer KL; Gore EM; Kwok Y; Seider MJ; Hsu IC; Hartford AC; Horwitz EM; Yamoah K; Jones CU; Michalski JM; Lee WR; Pisansky TM; Rabinovitch R; Rotman M; Pryzant RM; Kim HE; Thomas CR; Shipley WU; Sandler HM
    Lancet Oncol; 2018 Nov; 19(11):1504-1515. PubMed ID: 30316827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Analysis of Perioperative Outcomes on Neoadjuvant Hormone Therapy before Laparoscopic and Robot-Assisted Surgery for Localized High-Risk Prostate Cancer in a Chinese Cohort.
    Sun G; Liang Z; Jiang Y; Ma S; Chen S; Liu R
    Curr Oncol; 2022 Nov; 29(11):8668-8676. PubMed ID: 36421336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.
    Rajan P; Stockley J; Sudbery IM; Fleming JT; Hedley A; Kalna G; Sims D; Ponting CP; Heger A; Robson CN; McMenemin RM; Pedley ID; Leung HY
    BMC Cancer; 2014 Dec; 14():977. PubMed ID: 25519703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.